Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal
IASLC 2020 World Conference on Lung Cancer in SingaporeGiorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given decreases in mortality rates, widespread use of targeted treatments and immunotherapies, and earlier diagnoses as a result of systematic screening with low-dose CT (Abstract PL05.08).
Related Videos
Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success fo...
Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overal...
Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer
Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...
Jill Feldman on Diversifying the Criteria for Inclusion in Clinical Trials
Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved...
Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment
Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more ben...
